Genomma Lab Internacional, S.A.B. de C.V. Declares Second Cash Dividend Payment
May 31, 2022 at 08:22 pm IST
Share
Genomma Lab Internacional, S.A.B. de C.V. declaring a cash dividend on its common stock of MXN 0.381679389 per share, or a total amount of MXN 400,000,000.00, payable to shareholders of record at the close of business on June 2, 2022. This amount represents the total LABB shares currently in circulation This payment is in addition to the prior dividend paid on December 10, 2021 and therefore represents the total dividend approved at the Company's Ordinary and Extraordinary Annual General Shareholders Meeting held on April 27, 2017 which delegated to the Board of Directors the faculty to determine the payment dates of said dividends.
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Companyâs product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. 
